Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Progress Article
Nature Nanotechnology 4, 411–414 (1 July 2009) | doi:10.1038/nnano.2009.175
Evaluation of nanoparticle immunotoxicity
&
Abstract
The pharmaceutical industry is developing increasing numbers of drugs and diagnostics based on nanoparticles, and evaluating the immune response to these diverse formulations has become a challenge for scientists and regulatory agencies alike. An international panel of scientists and representatives from various agencies and companies reviewed the imitations of current tests at a workshop held at the National Cancer Institute in Frederick, Maryland. This article outlines practical strategies for identifying and controlling interferences in common evaluation methods and the implications for regulation.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
